´ëÀå¾Ï ȯÀÚÀÇ ¿Á»ì¸®Çöóƾ(oxaliplatin) À¯µµ ¸»ÃʽŰ溴Áõ¿¡ ´ëÇÑ ¾à¹°À¯ÀüÇÐÀû Á¢±Ù: ü°èÀû ¹®Çå°íÂû
Current Pharmacogenetic Approach for Oxaliplatin-induced Peripheral Neuropathy among Patients with Colorectal Cancer: A Systematic Review
Journal of Korean Biological Nursing Science 2018³â 20±Ç 2È£ p.55 ~ p.66
¾È¼öÁ¤(Ahn Soo-Jung) - ¿¬¼¼´ëÇб³ ´ëÇпø
ÃÖ¼Ò¿µ(Choi So-Young) - ¿¬¼¼´ëÇб³ ´ëÇпø
Á¤ÇýÁ¤(Jung Hye-Jeong) - ¼¼ºê¶õ½ºº´¿ø
Ãß»óÈñ(Chu Sang-Hui) - ¿¬¼¼´ëÇб³ °£È£´ëÇÐ
Abstract
Purpose: Peripheral neuropathy is common among colorectal cancer (CRC) patients who undergo oxaliplatin-based (OXL) chemo- therapy. A pharmacogenetic approach can be used to identify patients at high-risk of developing severe neuropathy. This type of ap- proach can also help clinicians determine the best treatment option and prevent severe neurotoxicity. The purpose of this study is to investigate the evidence of pharmacogenetic markers for OXL-induced peripheral neuropathy (OXIPN) in patients with CRC.
Methods: A systematic literature search was conducted using the following databases up to December 2017: Pubmed, EMBASE, and CI- NAHL. We reviewed the genetic risk factors for OXIPN in observational studies and randomized controlled clinical trials (RCTs). All pro- cesses were performed independently by two reviewers.
Results: Sixteen studies published in English between 2006 and 2017 were included in this review. A genome-wide association approach was used in one study and various candidate genes were tested, based on their functions (e.g., DNA damage or repair, ion channels, anti-oxidants, and nerve growth etc.). The genes associated with inci- dence or severity of OXIPN were ABCG2, GSTP1, XRCC1, TAC1, and ERCC1.
Conclusion: This study highlighted the need and the im- portance of conducting pharmacogenetic studies to generate evidence of personalized OXIPN symptoms management. Additional studies are warranted to accelerate the tailored interventions used for OXIPN in patients with CRC (NRF-2014R1A1A3054386).
Å°¿öµå
¿Á»ì¸®Çöóƾ, ¸»ÃʽŰ溴Áõ, ¾à¹°À¯ÀüÇÐ, ´ëÀå¾Ï
Oxaliplatin, Peripheralneuropathy, Pharmacogenetics, Colorectalcancer
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This study highlighted the need and the importance of conducting pharmacogenetic studies to generate evidence of personalized OXIPN symptoms management.